尤瑞克林治疗急性脑梗死的临床研究

目的探讨应用尤瑞克林治疗急性脑梗死的临床效果。方法选取急性脑梗死患者132例，随机分成两组，治疗组66例，给予0．9％生理盐水100mL＋尤瑞克林0．15PNA静脉滴注，1次／d，连用14d，对照组66例，应用疏血通6mL加入生理盐水250mL1次／d静点，连用14d，同时针对性地使用抗血小板药物、依达拉奉清除自由基及神经康复治疗，于治疗前后评定神经功能缺损程度（NIHSS）评分及临床疗效，监测血液流变学指标及血尿常规、血糖、血脂、肝肾功能，详细记录不良反应。结果治疗14d末，研究组显效率90．4％，总有效率98．2％。对照组显效率42．8％，总有效率78．5％。两组神经功能缺损评分较治疗前均有显著性下降，研究组较对照组下降显著，两组均未出现明显不良反应。结论尤瑞克林联合依达拉奉治疗急性脑梗死疗效显著，不良反应发生率低，值得临床推广应用。

Clinical Research of Urinary Kallindinogenase in the Treatment of Acute Cerebral Infarction

Objective To study the treatment of acute cerebral infarction by Urinary Kallindinogenase in clinical practice. Methods 132 cases of acute cerebral infarction patients were randomly divided into two groups, 66 cases in the treatment group were given 0.9% saline 100 m ＋ Urinary Kallidinogenase 0.15 PNA intravenous drip, once a day, for 14 d, 66 cases in the control group were given Shuxuetong Injection 6ml plus normal saline 250ml once daily static point, for 14 d, at the same time, Edaravone, an antiplatelet drug, was used to free radical scavenging and rehabilitation treatment. The neurological deficit （NIHSS） score and the clinical efficacy of two groups were evaluated before and after the treatment, the indexes of blood rheology and blood and urine routine, blood glucose, blood lipids, liver and kidney function of the groups were monitored, and the adverse reactions of the groups were recorded detailedly. Results After the treatment of 14 days, the markedly effective rate of the study group was 90.4%, the total efficiency was 98.2%, while that of the control group was 42.8% and 78.5%, respectively. The nerve function defect scores of two groups significantly decreased compared with those before the treatment, and those of the study group decreased more significantly than those of the control group. And no obvious adverse reactions occurred in both groups. Conclusion Urinary Kallindinogenase combined with Edaravone has significantly curative effect in treating acute cerebral infarction and low incidence of adverse reactions, which is worthy of clinical application.